{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:35:22Z","timestamp":1774352122422,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Key R&D Program of China","award":["2017YFA0105802"],"award-info":[{"award-number":["2017YFA0105802"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s10067-019-04880-z","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T16:02:48Z","timestamp":1576598568000},"page":"491-497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease"],"prefix":"10.1007","volume":"39","author":[{"given":"Yanying","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjie","family":"Bian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangnan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiali","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaozhen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingni","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0794-7646","authenticated-orcid":false,"given":"Zhanguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"issue":"9976","key":"4880_CR1","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60720-0","volume":"385","author":"T Kamisawa","year":"2015","unstructured":"Kamisawa T, Zen Y, Pillai S, Stone JH (2015) IgG4-related disease. Lancet 385(9976):1460\u20131471. https:\/\/doi.org\/10.1016\/S0140-6736(14)60720-0","journal-title":"Lancet"},{"issue":"2","key":"4880_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00296-017-3765-7","volume":"38","author":"S Yadlapati","year":"2018","unstructured":"Yadlapati S, Verheyen E, Efthimiou P (2018) IgG4-related disease: a complex under-diagnosed clinical entity. Rheumatol Int 38(2):169\u2013177. https:\/\/doi.org\/10.1007\/s00296-017-3765-7","journal-title":"Rheumatol Int"},{"issue":"7","key":"4880_CR3","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/art.39132","volume":"67","author":"A Khosroshahi","year":"2015","unstructured":"Khosroshahi A, Wallace ZS, Crowe JL et al (2015) International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 67(7):1688\u20131699. https:\/\/doi.org\/10.1002\/art.39132","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"4880_CR4","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1002\/art.39205","volume":"67","author":"ZS Wallace","year":"2015","unstructured":"Wallace ZS, Deshpande V, Mattoo H, Mahajan VS, Kulikova M, Pillai S, Stone JH (2015) IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol 67(9):2466\u20132475. https:\/\/doi.org\/10.1002\/art.39205","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"4880_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10165-011-0508-6","volume":"22","author":"H Umehara","year":"2012","unstructured":"Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, Matsui S, Sumida T, Mimori T, Tanaka Y, Tsubota K, Yoshino T, Kawa S, Suzuki R, Takegami T, Tomosugi N, Kurose N, Ishigaki Y, Azumi A, Kojima M, Nakamura S, Inoue D, Research Program for Intractable Disease by Ministry of Health, Labor and Welfare (MHLW) Japan G4 team (2012) A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol 22(1):1\u201314. https:\/\/doi.org\/10.1007\/s10165-011-0508-6","journal-title":"Mod Rheumatol"},{"key":"4880_CR6","doi-asserted-by":"publisher","unstructured":"Wang L, Zhang P, Wang M et al (2018) Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients. Arthritis Res Ther 20. https:\/\/doi.org\/10.1186\/s13075-018-1567-2","DOI":"10.1186\/s13075-018-1567-2"},{"issue":"1","key":"4880_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/rheumatology\/key227","volume":"58","author":"F Yunyun","year":"2019","unstructured":"Yunyun F, Yu P, Panpan Z, Xia Z, Linyi P, Jiaxin Z, Li Z, Shangzhu Z, Jinjing L, di W, Yamin L, Xiaowei L, Huadan X, Xuan Z, Xiaofeng Z, Fengchun Z, Yan Z, Wen Z (2019) Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial. Rheumatology (Oxford) 58(1):52\u201360. https:\/\/doi.org\/10.1093\/rheumatology\/key227","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"4880_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/rheumatology\/keu228","volume":"54","author":"M Yamamoto","year":"2015","unstructured":"Yamamoto M, Nojima M, Takahashi H, Yokoyama Y, Ishigami K, Yajima H, Shimizu Y, Tabeya T, Matsui M, Suzuki C, Naishiro Y, Takano K, Himi T, Imai K, Shinomura Y (2015) Identification of relapse predictors in IgG4-related disease using multivariate analysis of clinical data at the first visit and initial treatment. Rheumatology (Oxford) 54(1):45\u201349. https:\/\/doi.org\/10.1093\/rheumatology\/keu228","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"4880_CR9","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1016\/j.cgh.2018.02.049","volume":"16","author":"S Majumder","year":"2018","unstructured":"Majumder S, Mohapatra S, Lennon RJ, Piovezani Ramos G, Postier N, Gleeson FC, Levy MJ, Pearson RK, Petersen BT, Vege SS, Chari ST, Topazian MD, Witzig TE (2018) Rituximab maintenance therapy reduces rate of relapse of pancreaticobiliary immunoglobulin G4-related disease. Clin Gastroenterol Hepatol 16(12):1947\u20131953. https:\/\/doi.org\/10.1016\/j.cgh.2018.02.049","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"4880_CR10","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00535-018-1434-6","volume":"53","author":"HW Lee","year":"2018","unstructured":"Lee HW, Moon S-H, Kim M-H, Cho DH, Jun JH, Nam K, Song TJ, Park DH, Lee SS, Seo DW, Lee SK (2018) Relapse rate and predictors of relapse in a large single center cohort of type 1 autoimmune pancreatitis: long-term follow-up results after steroid therapy with short-duration maintenance treatment. J Gastroenterol 53(8):967\u2013977. https:\/\/doi.org\/10.1007\/s00535-018-1434-6","journal-title":"J Gastroenterol"},{"key":"4880_CR11","doi-asserted-by":"publisher","unstructured":"Ye Y, Liu M, Tang L et al (2019) Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC\/EGR1 axis. Arthritis Res Ther 21. https:\/\/doi.org\/10.1186\/s13075-019-1874-2","DOI":"10.1186\/s13075-019-1874-2"},{"issue":"5","key":"4880_CR12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1586\/1744666X.2015.1027151","volume":"11","author":"K Tanaka","year":"2015","unstructured":"Tanaka K, Yamaguchi T, Hara M (2015) Iguratimod for the treatment of rheumatoid arthritis in Japan. Expert Rev Clin Immunol 11(5):565\u2013573. https:\/\/doi.org\/10.1586\/1744666X.2015.1027151","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"4880_CR13","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41598-018-20390-5","volume":"8","author":"G Li","year":"2018","unstructured":"Li G, Yamasaki R, Fang M, Masaki K, Ochi H, Matsushita T, Kira JI (2018) Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages\/microglia through an NF-\u03baB pathway. Sci Rep 8(1):1933. https:\/\/doi.org\/10.1038\/s41598-018-20390-5","journal-title":"Sci Rep"},{"issue":"3","key":"4880_CR14","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1080\/14397595.2018.1481565","volume":"29","author":"K Ishikawa","year":"2019","unstructured":"Ishikawa K, Ishikawa J (2019) Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-\u03baB and production of RANKL: its efficacy, radiographic changes, safety and predictors over two years\u2019 treatment for Japanese rheumatoid arthritis patients. Mod Rheumatol 29(3):418\u2013429. https:\/\/doi.org\/10.1080\/14397595.2018.1481565","journal-title":"Mod Rheumatol"},{"issue":"10","key":"4880_CR15","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.4049\/jimmunol.1300832","volume":"191","author":"Q Luo","year":"2013","unstructured":"Luo Q, Sun Y, Liu W et al (2013) A novel disease-modifying Antirheumatic drug, Iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and Leflunomide. J Immunol 191(10):4969\u20134978. https:\/\/doi.org\/10.4049\/jimmunol.1300832","journal-title":"J Immunol"},{"issue":"9","key":"4880_CR16","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s10067-015-2999-6","volume":"34","author":"X-W Duan","year":"2015","unstructured":"Duan X-W, Zhang X-L, Mao S-Y, Shang J-J, Shi X-D (2015) Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial. Clin Rheumatol 34(9):1513\u20131519. https:\/\/doi.org\/10.1007\/s10067-015-2999-6","journal-title":"Clin Rheumatol"},{"issue":"3","key":"4880_CR17","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3109\/14397595.2013.843756","volume":"24","author":"M Hara","year":"2014","unstructured":"Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Yamamoto K, Iguratimod-Clinical Study Group (2014) Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 24(3):410\u2013418. https:\/\/doi.org\/10.3109\/14397595.2013.843756","journal-title":"Mod Rheumatol"},{"issue":"10","key":"4880_CR18","doi-asserted-by":"publisher","first-page":"e108273","DOI":"10.1371\/journal.pone.0108273","volume":"9","author":"Q Yan","year":"2014","unstructured":"Yan Q, Du F, Huang X et al (2014) Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL\/lpr mice. PLoS One 9(10):e108273. https:\/\/doi.org\/10.1371\/journal.pone.0108273","journal-title":"PLoS One"},{"issue":"8","key":"4880_CR19","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/1756-185X.13633","volume":"22","author":"P Zhang","year":"2019","unstructured":"Zhang P, Gong Y, Liu Z, Liu Y, Lin W, Li J, Wang M, Liu X, Fei Y, Chen H, Peng L, Li J, Zhou J, Shi Q, Zhang X, Shen M, Zeng X, Zhang F, Li Y, Zhao Y, Zhang W (2019) Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4-related diseases: a prospective clinical trial. Int J Rheum Dis 22(8):1479\u20131488. https:\/\/doi.org\/10.1111\/1756-185X.13633","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"4880_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10165-011-0571-z","volume":"22","author":"H Umehara","year":"2012","unstructured":"Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, Matsui S, Yoshino T, Nakamura S, Kawa S, Hamano H, Kamisawa T, Shimosegawa T, Shimatsu A, Nakamura S, Ito T, Notohara K, Sumida T, Tanaka Y, Mimori T, Chiba T, Mishima M, Hibi T, Tsubouchi H, Inui K, Ohara H (2012) Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 22(1):21\u201330. https:\/\/doi.org\/10.1007\/s10165-011-0571-z","journal-title":"Mod Rheumatol"},{"key":"4880_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/259408","volume":"2012","author":"MN Carruthers","year":"2012","unstructured":"Carruthers MN, Stone JH, Deshpande V, Khosroshahi A (2012) Development of an IgG4-RD responder index. Int J Rheumatol 2012:1\u20137. https:\/\/doi.org\/10.1155\/2012\/259408","journal-title":"Int J Rheumatol"},{"issue":"1","key":"4880_CR22","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.1038\/s41598-017-06520-5","volume":"7","author":"F Yunyun","year":"2017","unstructured":"Yunyun F, Yu C, Panpan Z, Hua C, di W, Lidan Z, Linyi P, Li W, Qingjun W, Xuan Z, Yan Z, Xiaofeng Z, Fengchun Z, Wen Z (2017) Efficacy of cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids. Sci Rep 7(1):6195. https:\/\/doi.org\/10.1038\/s41598-017-06520-5","journal-title":"Sci Rep"},{"issue":"1","key":"4880_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-28405-x","volume":"8","author":"M Shirakashi","year":"2018","unstructured":"Shirakashi M, Yoshifuji H, Kodama Y, Chiba T, Yamamoto M, Takahashi H, Uchida K, Okazaki K, Ito T, Kawa S, Yamada K, Kawano M, Hirata S, Tanaka Y, Moriyama M, Nakamura S, Kamisawa T, Matsui S, Tsuboi H, Sumida T, Shibata M, Goto H, Sato Y, Yoshino T, Mimori T (2018) Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study. Sci Rep 8(1):1\u20138. https:\/\/doi.org\/10.1038\/s41598-018-28405-x","journal-title":"Sci Rep"},{"issue":"6","key":"4880_CR24","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","volume":"74","author":"MN Carruthers","year":"2015","unstructured":"Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S, Stone JH (2015) Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 74(6):1171\u20131177. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206605","journal-title":"Ann Rheum Dis"},{"issue":"4 Suppl 98","key":"4880_CR25","first-page":"66","volume":"34","author":"JH Stone","year":"2016","unstructured":"Stone JH (2016) IgG4-related disease: pathophysiologic insights drive emerging treatment approaches. Clin Exp Rheumatol 34(4 Suppl 98):66\u201368","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"4880_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183844","volume":"12","author":"M Ebbo","year":"2017","unstructured":"Ebbo M, Grados A, Samson M, Groh M, Loundou A, Rigolet A, Terrier B, Guillaud C, Carra-Dalli\u00e8re C, Renou F, Pozdzik A, Labauge P, Palat S, Berthelot JM, Pennaforte JL, Wynckel A, Lebas C, le Gouellec N, Qu\u00e9meneur T, Dahan K, Carbonnel F, Leroux G, Perlat A, Mathian A, Cacoub P, Hachulla E, Costedoat-Chalumeau N, Harl\u00e9 JR, Schleinitz N (2017) Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients. PLoS One 12(9):e0183844. https:\/\/doi.org\/10.1371\/journal.pone.0183844","journal-title":"PLoS One"},{"issue":"1","key":"4880_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13075-017-1231-2","volume":"19","author":"W Lin","year":"2017","unstructured":"Lin W, Zhang P, Chen H, Chen Y, Yang H, Zheng W, Zhang X, Zhang F, Zhang W, Lipsky PE (2017) Circulating plasmablasts\/plasma cells: a potential biomarker for IgG4-related disease. Arthritis Res Ther 19(1):25. https:\/\/doi.org\/10.1186\/s13075-017-1231-2","journal-title":"Arthritis Res Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04880-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04880-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04880-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:49:47Z","timestamp":1608079787000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04880-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,17]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["4880"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04880-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,17]]},"assertion":[{"value":"18 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}